Cystic Fibrosis (CF) - Drug Pipeline Analysis and Market Forecasts to 2015

London, United Kingdom (PressExposure) December 22, 2009 -- CF is a genetic disease caused by an abnormal gene, affecting more than 70,000 people worldwide and ranked as one of the most prevalent life-shortening disease. It is most commonly diagnosed in populations of white caucasian descent, such as those of Europe, North America and Australasia. Currently, the median predicted age of survival for a person with CF is more than 37 years. GlobalData has found that the CF market has huge unmet needs compared to other markets, and that patient still show moderate responses to the two currently approved key products (excluding Zenpep).

The market is wide open for novel entrants to change the current treatment paradigm. The options in the market are only for symptomatic treatment which targets the antibiotic therapy and mucus regulations in CF patients. Other treatment therapies, such as pancreatic enzyme replacement therapy, ion channel therapy, mucolytic, and anti-inflammatory drugs, hope to become the leading products in the treatment of CF and the market is expected to be a relatively open until 2015 with huge opportunities for value capture.

For further details on this report, please click or add the below link to your browser

GlobalData has found that products for CF in the developmental pipeline are strong with over 88 molecules in various phases of clinical development. There are eight first-in-class molecules in Phase III stage of clinical development and these have a distinct advantage over the current marketed players. These molecules are primarily first-in-class molecules displaying the robustness of the CF pipeline as the market is demanding new entrants with novel treatments and re-formulation designs to improve the lung functions and overall patient and physician satisfaction.

There are 10 molecules in Phase III, while the Phase II pipeline is rich and comprises 44 molecules and forms 50% of the total CF pipeline. Cayston (aztreonam lysine), Denufosol tetrasodium inhalation solution (INS37217), VX-770, Bronchitol and Ataluren (PTC-124) are the key products currently in Phase III with features such as better efficacy, better tolerability and safety profiles. Pipeline is rich with novel therapies and mechanisms, also the clinical studies have shown these products with better safety and efficacy profile, which are hoping for an effective treatment options for patients with CF.

For further details on this report, please click or add the below link to your browser

GlobalData, the industry analysis specialist, has released a new report, “Cystic Fibrosis – Drug Pipeline Analysis and Market Forecasts to 2015.” The report is an essential source of information and analysis on the global cystic fibrosis (CF) market. The report identifies the key trends shaping and driving the global CF market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global CF sector.

For further details on this report, please click or add the below link to your browser

Or Visit our report store

About GlobalData

GlobalData is a global market intelligence services company providing information research and analysis products and services.

Press Release Source:

Press Release Submitted On: December 22, 2009 at 12:40 am
This article has been viewed 21916 time(s).